For sales

Highlights from the Week of 20th July – 27th July in the world of pharma and healthcare!

Highlights from the week of 20th July - 27th July GSK ( FDA, Approval ) GSK gets FDA approval for JIDEYTRO to treat adults with locally advanced or metastatic ROS1-positive NSCLC who received prior ROS1 kinase inhibitor Pfizer ( FDA, Priority Review ) FDA accepts Pfizer's sNDA, TALZENNA in combination with XTANDI for Priority Review, indicated to treat HRR gene-mutated mCRPC in US men Glenmark ( FDA, Approval ) FDA approves Glenmark's RYALTRIS Nasal Spray, 665 mcg/25 mcg per spray for expanded use, to treat symptoms of SAR in pediatrics aged 6 to less than 12 years AstraZeneca ( EU, Approval ) EC approves AstraZeneca's ETCAMAH in combination with a CDK 4/6 inhibitor for the treatment of adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.